Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
01. Februar 2019 05:04 ET
|
Lupin Ltd
Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 1 February 2019: Lupin is pleased to...
Lupin Limited: Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
08. Januar 2019 00:00 ET
|
Lupin Neurosciences Ltd
Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 8 January 2019: Lupin is pleased to announce that the...
Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
19. Oktober 2018 07:44 ET
|
Lupin Neurosciences Ltd
Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, October 19, 2018: Lupin Neurosciences, a...